Related by context. All words. (Click for frequent words.) 75 antitumor activity 74 heavily pretreated 74 ganetespib 73 heavily pretreated patients 73 Blinatumomab 72 xenograft models 72 PXD# 72 imatinib therapy 71 ENMD # 71 microtubule targeting 71 seliciclib 71 CA4P 71 pomalidomide 70 Symadex 70 potent antiviral 70 estramustine 70 mTOR inhibitors 70 erythropoietic 70 OXi# 70 antitumor 70 decitabine 70 IMC A# 69 pharmacodynamic PD 69 Tyrima 69 Carfilzomib 69 antithrombotic 69 Xanafide 69 riociguat 69 Seliciclib 69 pharmacokinetic interactions 69 depsipeptide 69 anticancer activity 69 favorable pharmacokinetic profile 69 GRN#L 69 tolerability profiles 69 sunitinib Sutent ® 69 HGS ETR2 69 preclinically 69 imatinib Gleevec ® 69 Doxil ® 69 HGS ETR1 69 pegylated liposomal doxorubicin 69 erlotinib Tarceva ® 69 antiangiogenic 69 DACH platinum 69 immunomodulatory 69 selective modulator 69 Aplidin 69 posaconazole 68 axitinib 68 solithromycin 68 tolerability profile 68 cytoprotective 68 relapsed refractory 68 APTIVUS r 68 Cloretazine 68 liposomal formulation 68 Perifosine 68 Bezielle 68 INCB# [001] 68 ON #.Na 68 enzastaurin 68 effector function 68 YONDELIS 68 uric acid lowering 68 viral kinetics 68 pharmacokinetic properties 68 elacytarabine 68 overlapping toxicities 68 receptor inhibitor 68 sorafenib Nexavar 68 sunitinib malate 68 pro apoptotic 68 Pemetrexed 68 bendamustine 68 immunomodulator 68 pharmacodynamic 67 mapatumumab 67 nab paclitaxel 67 HSP# inhibitor 67 antitumour activity 67 glucose lowering 67 topotecan 67 urate lowering 67 orally bioavailable 67 #ME# 67 Aurora kinase 67 immunomodulating 67 imatinib resistant 67 imetelstat 67 Traficet EN 67 azacitidine 67 vidofludimus 67 angiogenesis inhibitor 67 tocilizumab 67 teriflunomide 67 receptor tyrosine kinase inhibitor 67 APOPTONE 67 pharmacodynamic properties 67 Tarceva TM 67 alvespimycin 67 neurotrophic 67 amrubicin 67 Gleevec resistant 67 PRT# 67 sunitinib 67 CYC# 67 Gefitinib 67 dasatinib Sprycel 67 pharmacodynamic profile 67 antiviral activity 67 partial agonist 67 VNP#M 67 milatuzumab 67 CR# vcMMAE 67 antitumor efficacy 67 immune modulating 67 oral prodrug 67 obatoclax 67 imatinib Gleevec 67 GMX# 67 dosage regimens 66 Vidofludimus 66 MAGE A3 ASCI 66 PRTX 66 MGCD# [001] 66 indibulin 66 cilengitide 66 leukemia AML 66 trabectedin 66 metastatic renal cell carcinoma 66 fibrinolytic 66 Enzastaurin 66 BAY #-# 66 fosbretabulin 66 lenalidomide dexamethasone 66 CYT# potent vascular disrupting 66 hA# 66 crizotinib PF # 66 refractory CTCL 66 ACZ# 66 bortezomib 66 MGd 66 relapsed MM 66 sorafenib Nexavar ® 66 CIMZIA ™ 66 lintuzumab 66 S/GSK# 66 K ras mutations 66 CDK inhibitor 66 antitumor effects 66 pharmacodynamics PD 66 Omacetaxine 66 trastuzumab Herceptin ® 66 gemcitabine Gemzar 66 antiviral efficacy 66 potent antiproliferative 66 pharmacokinetic profile 66 thalidomide Thalomid 66 relapsed ovarian cancer 66 Omacetaxine mepesuccinate 66 recurrent glioblastoma multiforme 66 anti fibrotic 66 pharmacokinetic characteristics 66 nucleoside analog 66 cytotoxic chemotherapy 66 selective inhibition 66 Preclinical studies 66 Dasatinib 66 bortezomib Velcade 66 myeloproliferative diseases 66 chemotherapeutic drug 66 Virulizin ® 66 VAPRISOL 66 Cytoxan 66 Voreloxin 66 idarubicin 66 immunostimulatory 66 voreloxin 66 complete remissions 66 HCD# [002] 66 plasma kallikrein inhibitor 66 HQK 66 pertuzumab 66 Hematologic toxicity 66 AEG# 66 pharmacokinetic PK 66 XmAb# 65 interferon alfa 65 mycophenolate mofetil 65 dose limiting toxicities 65 immunomodulation 65 insulin sensitizing 65 CBLC# 65 tigecycline 65 vinorelbine 65 pharmacodynamics 65 HuMax EGFr 65 potent anti angiogenic 65 protease inhibitor PI 65 galiximab 65 JAK inhibitors 65 ELACYT 65 daunorubicin 65 PEG SN# 65 neurologic progression 65 mecamylamine 65 Apoptone 65 phase Ib 65 biodistribution 65 anti proliferative 65 antitumor effect 65 ZOLINZA 65 gemcitabine cisplatin 65 genotypic resistance 65 bronchodilation 65 pan HDAC inhibitor 65 Telintra 65 CLORETAZINE TM VNP#M 65 tyrosine kinase inhibitor 65 combinability 65 relapsed refractory multiple myeloma 65 PSN# [002] 65 LHRH antagonists 65 SCH # 65 LY# [003] 65 CYT# 65 samalizumab 65 limiting toxicity 65 PSMA ADC 65 lupus nephritis 65 safety tolerability pharmacokinetic 65 metastatic RCC 65 mertansine 65 vascular disrupting agents 65 antitumoral 65 melphalan prednisone 65 vandetanib 65 anti angiogenic 65 delafloxacin 65 MEK inhibitors 65 targeting CD# 65 Akt inhibitor 65 multitargeted 65 inhibitory effects 65 ZD# [001] 65 tipifarnib 65 IMGN# 65 proteasome inhibitors 65 Sym# 65 Hsp# inhibitors 65 HER2 positive metastatic breast 65 BRAF inhibitor 65 dasatinib 65 Akt activation 65 TRAIL induced apoptosis 65 Amrubicin 65 pharmacodynamic effects 65 bevacizumab Avastin ® 65 hematologic toxicity 65 GLYX 65 sorafenib 65 vinca alkaloid 65 Vidaza azacitidine 65 gefitinib Iressa 65 vorinostat 65 HuLuc# 65 platelet inhibitor 65 sapacitabine 65 CANCIDAS 65 antiandrogens 65 protein kinase inhibitor 65 vascular disrupting agent 65 ritonavir boosted 65 caspofungin 65 Azedra 65 glufosfamide 65 erlotinib 65 HGS# 65 cyclophosphamide Cytoxan 65 mg kg dose 65 IFN beta 65 remyelination 65 histone deacetylase inhibitor 65 talabostat 65 TNFalpha 65 vascular disrupting 65 Erlotinib 65 antiproliferative 65 cytostatic 65 temsirolimus 65 5FU 64 selective agonist 64 panitumumab Vectibix 64 potent anticancer 64 chronic lymphocytic leukemia CLL 64 FOLFIRI 64 bleomycin 64 neratinib 64 cis retinoic acid 64 erlotinib Tarceva 64 mGluR5 NAM 64 reversible inhibitor 64 Panzem R NCD 64 mTOR inhibitor 64 Kinoid 64 adalimumab 64 docetaxel chemotherapy 64 chemopreventive agent 64 gemcitabine carboplatin 64 CCX# 64 ALB # 64 rFIXFc 64 Bortezomib 64 forodesine 64 tumor necrosis 64 factor TNF 64 anticancer agent 64 paclitaxel Taxol 64 cytotoxicity 64 EGFR tyrosine kinase inhibitors 64 AP# [003] 64 oblimersen 64 fibrotic disease 64 proteasome inhibitor 64 BAL# [001] 64 paricalcitol 64 Aplidin R 64 FGFR 64 interferon IFN 64 DMARD 64 Mitoxantrone 64 tumor regression 64 tanespimycin 64 oral bioavailability 64 alkylating agent 64 mRCC 64 maximally tolerated dose 64 TNFα 64 HCV protease 64 Interferon alpha 64 favorable tolerability 64 ovarian carcinoma 64 etoposide 64 Talactoferrin 64 superficial bladder cancer 64 DXL# 64 investigational humanized monoclonal antibody 64 nephrotoxicity 64 pharmacokinetics PK 64 immunological responses 64 CCR2 64 mTOR inhibition 64 ascending dose 64 Pazopanib 64 LMWH 64 antiarrhythmic 64 antidepressant efficacy 64 orally dosed 64 Talabostat 64 preclinical efficacy 64 hypoxia inducible factor 64 demonstrated antitumor activity 64 Cloretazine R VNP#M 64 fluvastatin 64 adalimumab Humira 64 azacytidine 64 CTAP# Capsules 64 antiangiogenic activity 64 anti angiogenic agents 64 GRN# 64 nilotinib 64 Targretin 64 standard chemotherapy regimen 64 tolerability 64 selective inhibitor 64 PKC# 64 virologic responses 64 PREZISTA r 64 SERCA2a 64 intratumoral injection 64 tipranavir 64 dose escalation Phase 64 mg/m2 cohort 64 cabazitaxel 64 IFN α 64 T#I [002] 64 flavopiridol 64 nitazoxanide 64 HRPC 64 ponatinib 64 bicalutamide 64 antineoplastic 64 docetaxel Taxotere ® 64 investigational monoclonal antibody 64 metaglidasen 64 mitomycin 64 multi kinase inhibitor 64 APTIVUS 64 antiangiogenic therapy 64 canakinumab 64 Aflibercept 64 durable remissions 64 adriamycin 64 abiraterone acetate 64 dacetuzumab 64 Angiolix 64 romidepsin 64 cytokine refractory 64 cytotoxic agents 64 EGFR HER2 64 TG# [003] 64 antiapoptotic 64 selective antagonist 64 carboplatin paclitaxel 64 ara C 64 Trastuzumab 64 urocortin 2 64 Quinamed 64 Vorinostat 64 favorable pharmacokinetic 63 cediranib 63 retapamulin 63 radiation sensitizer 63 dasatinib Sprycel ® 63 virologic response 63 lipid lowering therapies 63 dose escalation 63 NNRTIs 63 ISIS # 63 prednisone prednisolone 63 potent antitumor activity 63 relapsed SCLC 63 muscarinic 63 chemotherapy docetaxel 63 antidiabetic 63 histone deacetylases 63 tumor xenograft models 63 Tarvacin 63 CD# antibody [001] 63 NXL# 63 TELCYTA 63 velafermin 63 EndoTAGTM 1 63 CIMZIA TM 63 enfuvirtide 63 secretory phospholipase A2 sPLA2 63 surrogate endpoint 63 glucagon receptor 63 HMG CoA reductase inhibitor 63 irreversible inhibitor 63 resistant ovarian cancer 63 Triolex 63 antiangiogenic agents 63 OHR/AVR# 63 liposomal doxorubicin 63 taxanes 63 Hsp# inhibition 63 cytotoxic 63 Imprime PGG 63 pharmacokinetic profiles 63 EGFR inhibitors 63 dose cohorts 63 Tamibarotene 63 vitro cytotoxicity 63 docetaxel Taxotere 63 5 HT6 receptor 63 chlorambucil 63 PDE4 inhibitor 63 cardiac toxicity 63 DLTs 63 adecatumumab 63 Combination therapy 63 plasma renin activity 63 PEGylated interferon beta 1a 63 BZL# 63 coadministration 63 INCB# [003] 63 TELINTRA 63 ixabepilone 63 phase IIb clinical 63 leukemia CLL 63 refractory acute myeloid 63 CXB# 63 tumorigenicity 63 vemurafenib 63 taxane refractory 63 tumor subtypes 63 JAK3 63 CHOP chemotherapy 63 fulvestrant 63 CGRP 63 linear pharmacokinetics 63 anticancer therapy 63 EGFR antibodies 63 EGFR TKI 63 IAP inhibitor 63 IMA# 63 OMP #M# 63 perifosine 63 biologic therapy 63 evaluating tivozanib 63 somatostatin analogue 63 immune stimulatory 63 AMN# [001] 63 monotherapy 63 olmesartan 63 lenalidomide Revlimid R 63 DAPT 63 metastatic malignant melanoma 63 potentially hepatotoxic 63 Pharmacokinetic studies 63 EGFR tyrosine kinase inhibitor 63 platinum refractory 63 factor Xa inhibitor 63 clinically meaningful differences 63 Pralatrexate 63 pharmacologic 63 dosing cohort 63 CG# [003] 63 DAVANAT 63 intravenous dosing 63 bosentan 63 nucleoside analogs 63 mitogenic 63 PI3K Akt 63 TNF α 63 HCV protease inhibitors 63 transgene expression 63 elotuzumab 63 oral antiviral 63 KRAS status 63 pheochromocytoma 63 cinacalcet 63 PEGylated 63 IFN alpha 63 DFMO 63 oxidative stress inducer 63 Onconase 63 RGB # 63 Teriflunomide 63 taxane therapy 63 Ceflatonin 63 otelixizumab 63 low dose cytarabine 63 anti amnesic 63 LUX Lung 63 Taxol paclitaxel 63 synthase TS 63 osteoclastic 63 Epratuzumab 63 varespladib 63 oral JAK1 63 inotropic 63 systemically administered 63 intravenous cyclophosphamide 63 octreotide 63 refractory AML 63 metastatic malignant 63 molecularly targeted 63 neurotoxicity 63 rindopepimut 63 hypomethylating agents 63 antiresorptive 63 pegylated 63 imatinib 63 BNC# 63 rituximab 63 Fulvestrant 63 glatiramer acetate 63 TriRima 63 Elacytarabine 63 mg/m2 dose 63 mitoxantrone 63 nucleotide analog 63 Romidepsin 63 systemic absorption 63 vicriviroc 63 androgen independent 63 orally administered inhibitor 63 antiangiogenic agent 63 tumor regressions 63 Pegasys ® 63 kinase inhibition 63 retaspimycin 63 DOXIL 63 Immunohistochemical analysis 63 interleukin IL -# 63 neuroprotective properties 63 QTc prolongation 63 Phase 2a trial 63 mCRC patients 63 induce apoptosis 63 thrombopoietin 63 pemetrexed 63 highly immunogenic 63 interferon alfa 2b 63 Valortim ® 62 SERMs 62 gemcitabine Gemzar ® 62 androgen deprivation 62 XL# inhibits 62 FOLFOX6 62 potent neuroprotective 62 gemcitabine 62 doxorubicin docetaxel 62 chemotherapeutic agents 62 vWF 62 Pharmacokinetics PK 62 small molecule tyrosine 62 oxaliplatin Eloxatin 62 sustained virological response 62 molecular weight heparins 62 PI3K inhibitor 62 nucleoside analogues 62 histologies 62 Fludarabine 62 renal toxicity 62 MabCampath 62 immunomodulatory therapy 62 panobinostat 62 BAL# [002] 62 apremilast 62 activin 62 dexamethasone Decadron 62 downregulation 62 Vandetanib 62 pazopanib 62 Phase Ib study 62 Golimumab 62 sodium glucose cotransporter 62 TNFa 62 PCK# 62 OncoVEX GM CSF 62 novel VDA molecule 62 immunoregulatory 62 ranolazine 62 Atiprimod 62 Valortim R 62 angiogenesis inhibition 62 bone metastasis 62 calcitriol 62 tiotropium 62 MYDICAR ® 62 PEGylated Fab fragment 62 XL# SAR# 62 motesanib 62 myelosuppression 62 JAK2 inhibitors 62 veltuzumab 62 Cloretazine ® 62 paclitaxel Taxol ® 62 NS#/#A protease 62 selectively inhibited 62 eniluracil 62 Annamycin 62 PNP inhibitor 62 temozolomide 62 adrenal suppression 62 iniparib 62 plasma pharmacokinetics 62 novel peptide 62 Adalimumab 62 T2DM 62 TO AVOID PREGNANCY WHILE 62 FOLPI 62 pharmacodynamic profiles 62 Subgroup analysis 62 proteasome inhibitor bortezomib 62 Alocrest 62 multikinase inhibitor 62 visilizumab 62 nanomolar 62 tolerated dose MTD 62 Dapagliflozin 62 pharmacokinetic 62 fluoropyrimidine 62 MERLIN TIMI 62 cytarabine daunorubicin 62 IGF 1R inhibitor 62 anti EGFR antibody 62 FUSILEV enhances 62 ZYBRESTAT 62 immunomodulatory effects 62 Insulin PH# 62 nonclinical studies 62 D aspartate NMDA receptor 62 brostallicin 62 HER2 overexpression 62 Plicera 62 ATL/TV# 62 cMET 62 MetMAb 62 farletuzumab 62 alagebrium 62 TOP2A 62 TTF Therapy 62 R roscovitine 62 GFT# 62 eltrombopag 62 vismodegib 62 tumor vasculature 62 VEGF receptor 62 FK# 62 IRX 2 62 HIF PHI 62 demethylating agents 62 alefacept 62 IL 1ß 62 hematologic malignancies 62 PROCHYMAL 62 CYP #A# 62 cetuximab Erbitux ® 62 EndoTAG TM -1 62 GRASPA ® 62 targeted antifolate 62 vitro antiviral 62 antifibrotic 62 Amplimexon 62 dose proportionality 62 Thiovir 62 #D#C# 62 nucleoside analogue 62 rBChE 62 lumiliximab 62 uricase 62 relapsed multiple myeloma 62 radezolid 62 rhIGFBP 3 62 Sapacitabine 62 TRV# [001] 62 gamma secretase inhibitor 62 refractory multiple myeloma 62 subcutaneously administered 62 cancer mCRC 62 JAK2 inhibitor 62 chemoradiotherapy 62 administered subcutaneously 62 hematological tumors 62 pharmacokinetics 62 Antitumor Activity 62 HDACi 62 Tasimelteon 62 ascending doses 62 potent cytotoxic 62 EGFr 62 Panzem NCD 62 Archexin 62 sorafenib tablets 62 JVRS 62 Janus kinase 62 micafungin 62 indolent NHL 62 direct thrombin inhibitors 62 desvenlafaxine succinate 62 Aliskiren 62 hour bronchodilation 62 trastuzumab 62 HuMax CD# 62 acute leukemias 62 c MET 62 olaparib 62 ALK inhibitor 62 anti VEGF 62 idraparinux 62 Degarelix 62 Pertuzumab 62 Fludara 62 kinase inhibitor 62 AQ4N 62 microglial activation 62 HuMax CD4 62 ADP receptor antagonist 62 cisplatin gemcitabine 62 AAG geldanamycin analog 62 intravenously administered 62 immune modulatory 62 NNRTI resistance 62 SCCHN 62 VEGFb 62 hepatic fibrosis 62 TRIOLEX 62 DU #b 62 triphendiol 62 INGN 62 Aptivus ® 62 AKT inhibitor 62 dosing regimens 62 chemotherapeutic agent 62 busulfan 62 neuroprotectant 62 raltegravir 62 antimetabolite 62 HCV replicon 62 pro angiogenic 62 Onrigin 62 chemopreventive 62 humanized anti 62 Nilotinib 62 bevacizumab Avastin 62 splenectomized patients 62 LEP ETU 62 gefitinib 62 antiretroviral naive 62 Phase Ib II 62 cyclin E 62 vitro experiments 62 Lacosamide 62 immunostimulatory effects 62 Azixa 62 mGluR2 NAM 62 #beta HSD1 62 Etoposide 62 trans retinoic acid 62 anthracycline 62 LY# [002] 62 neuroregenerative 62 rituximab Rituxan 62 dose cytarabine 62 RDEA# 62 antiproliferative effects 61 analgesic efficacy 61 trabedersen 61 plasma kallikrein 61 virological response 61 pharmacokinetics pharmacodynamics 61 inhibitor RG# 61 pathophysiological effects 61 T#I mutant 61 entinostat 61 recurrent ovarian cancer 61 CoFactor 61 masitinib 61 MGCD# [002] 61 randomized Phase 2b 61 CD# expressing 61 doxorubicin cyclophosphamide 61 antibody MAb 61 VELCADE melphalan 61 prospectively defined 61 GHRH 61 Abatacept 61 neoadjuvant chemotherapy 61 elesclomol 61 ibandronate 61 intranasal delivery 61 davunetide intranasal AL 61 BMS# 61 paclitaxel Taxol R 61 preclinical studies 61 rilonacept 61 5 HT2A receptor 61 corticosteroid dexamethasone 61 interferon therapy 61 Pharmacokinetic 61 JAK inhibitor 61 telomerase inhibition 61 EGFR expressing 61 NOX E# 61 epithelial tumors 61 standard chemotherapy regimens 61 novel anticancer 61 dose dependently 61 Solorel TM 61 angiotensin receptor blocker ARB 61 Zolinza 61 Darinaparsin 61 LRP5 61 leukemia ALL 61 prostate cancer CRPC 61 complete cytogenetic response 61 echinocandin 61 apoptosis inducer 61 etanercept 61 calcineurin inhibitors 61 fluticasone furoate 61 leukemic cell 61 PROSTVAC VF 61 TKI therapy 61 hematological cancers 61 hENT1 61 lung fibrosis 61 HBeAg positive 61 Bevacizumab 61 Adjuvant chemotherapy 61 ENMD 61 AZT zidovudine Retrovir 61 fosamprenavir 61 EGFR TKIs 61 relapsed myeloma 61 RezularTM 61 miglustat 61 PDE4 inhibitors 61 novel histone deacetylase 61 β blockers 61 IGFBP 3 61 TMC# [002] 61 pamidronate 61 Aurora Kinase 61 mouse xenograft models 61 phase IIb trial 61 NEUGENE 61 MET amplification 61 HCV SPRINT 61 nucleotide analogs 61 lapatinib Tykerb 61 oral Hycamtin 61 xanthine oxidase inhibitor 61 ARIKACE 61 immune modulator 61 Laquinimod 61 INCB# [002] 61 Ophena TM 61 bezafibrate 61 pharmacodynamic markers 61 LHRH agonists 61 abatacept 61 cannabinor 61 5-FU/LV 61 TREANDA 61 Panzem R 61 tumorigenic 61 TACE 61 Phase 1b trial 61 KRN# 61 EDEMA3 trial 61 IL 1β 61 leukemic stem cells 61 anti mitotic 61 potent inhibitor 61 teduglutide 61 nutlin 61 histone deacetylase HDAC inhibitor 61 ISTODAX 61 Panzem 61 polymerase inhibitor 61 Arranon 61 Anthracycline 61 AT1R 61 HIV HCV coinfected 61 flutamide 61 Genz # 61 induces apoptosis 61 GPIIb IIIa 61 HMG CoA reductase inhibitors 61 NLX P# 61 Navelbine ® 61 insulin sensitizers 61 AMD# [003] 61 selective kinase inhibitor 61 KSP inhibitors 61 CIMZIA TM certolizumab pegol 61 LT NS# 61 neoadjuvant 61 IRESSA 61 R#/MEM # 61 liposome formulation 61 Revlimid lenalidomide 61 registrational trial 61 Rasagiline 61 TNF inhibitors 61 AEGR 61 Triapine R 61 recurrent glioblastoma 61 dose proportional pharmacokinetics 61 potency selectivity 61 tesmilifene 61 hypercalcemia 61 sipuleucel T 61 Taxotere chemotherapy 61 selectively inhibits 61 thrombin receptor 61 basal bolus regimen 61 plasma uric acid 61 anti resorptive 61 Irinotecan 61 anxiolytic 61 MAPK pathway 61 EOquin TM 61 huC# DM4 61 TORISEL 61 NRTI 61 CCyR 61 noninferiority 61 Amphinex ® 61 systemic antifungal 61 EGFR mutation positive 61 antiinflammatory 61 IL #E 61 OncoVEX 61 5 fluorouracil 61 disease modifying antirheumatic 61 noninfectious uveitis 61 intermittent dosing 61 chemotherapeutic regimen 61 huN# DM1 61 Denufosol 61 HDAC 61 cetuximab Erbitux R